Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features.
Miller
W H
WH
Lady Davis Institute, Montreal, Quebec, Canada.
D002454:Cell Differentiation / Q000187:drug effects; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy*; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D011446:Prospective Studies; D012334:RNA, Neoplasm / Q000737:chemistry; D018168:Receptors, Retinoic Acid / Q000235:genetics; D000072482:Retinoic Acid Receptor alpha; D016019:Survival Analysis; D014157:Transcription Factors / Q000235:genetics; D014178:Translocation, Genetic / Q000187:drug effects; D014212:Tretinoin / Q000627:therapeutic use*; D025521:Tumor Suppressor Proteins
D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; C000607071:RARA protein, human; D012334:RNA, Neoplasm; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human; D014212:Tretinoin